INDUCED PLURIPOTENT STEM CELL-DERIVED MESENCHYMAL STEM CELLS-DERIVED EXTRACELLULAR VESICLES ATTENUATE LPS-INDUCED LUNG INJURY AND ENDOTOXEMIA IN MICE

Overview

Journal Shock

Date 2024 May 30

PMID 38813932

Authors

Qinghe Meng

Tackla Winston

Julia Ma

Yuanhui Song

Chunyan Wang

Junhui Yang

Zhen Ma

Robert N Cooney

Affiliations

Soon will be listed here.

Abstract

Introduction: We hypothesized extracellular vesicles (EVs) from preconditioned human-induced pluripotent stem cell-derived mesenchymal stem cells (iMSCs) attenuate LPS-induced acute lung injury (ALI) and endotoxemia. Methods: iMSCs were incubated with cell stimulation cocktail (CSC) and EVs were isolated. iMSC-EVs were characterized by size and EV markers. Biodistribution of intratracheal (IT), intravenous, and intraperitoneal injection of iMSC-EVs in mice was examined using IVIS. Uptake of iMSC-EVs in lung tissue, alveolar macrophages, and RAW264.7 cells was also assessed. C57BL/6 mice were treated with IT/IP iMSC-EVs or vehicle ± IT/IP LPS to induce ALI/acute respiratory distress syndrome and endotoxemia. Lung tissues, plasma, and bronchoalveolar lavage fluid (BALF) were harvested at 24 h. Lung histology, BALF neutrophil/macrophage, cytokine levels, and total protein concentration were measured to assess ALI and inflammation. Survival studies were performed using IP LPS in mice for 3 days. Results: iMSC-EV route of administration resulted in differential tissue distribution. iMSC-EVs were taken up by alveolar macrophages in mouse lung and cultured RAW264.7 cells. IT LPS-treated mice demonstrated marked histologic ALI, increased BALF neutrophils/macrophages and protein, and increased BALF and plasma TNF-α/IL-6 levels. These parameters were attenuated by 2 h before or 2 h after treatment with IT iMSC-EVs in ALI mice. Interestingly, the IT LPS-induced increase in IL-10 was augmented by iMSC-EVs. Mice treated with IP LPS showed increases in TNF-α and IL-6 that were downregulated by iMSC-EVs and LPS-induced mortality was ameliorated by iMSC-EVs. Administration of IT iMSC-EVs 2 h after LPS downregulated the increase in proinflammatory cytokines (TNF-α/IL-6) by LPS and further increased IL-10 levels. Conclusions: iMSC-EVs attenuate the inflammatory effects of LPS on cytokine levels in ALI and IP LPS in mice. LPS-induced mortality was improved with administration of iMSC-EVs.

Citing Articles

Mesenchymal Stem Cell-Derived Extracellular Vesicles for Regenerative Applications and Radiotherapy.

Wang N, Ma F, Song H, He N, Zhang H, Li J Cell Transplant. 2025; 34():9636897241311019.

PMID: 39780320 PMC: 11713979. DOI: 10.1177/09636897241311019.

Megakaryocyte in sepsis: the trinity of coagulation, inflammation and immunity.

Hua T, Yao F, Wang H, Liu W, Zhu X, Yao Y Crit Care. 2024; 28(1):442.

PMID: 39741325 PMC: 11689543. DOI: 10.1186/s13054-024-05221-6.

References

Menasche P . Cell therapy trials for heart regeneration - lessons learned and future directions. Nat Rev Cardiol. 2018; 15(11):659-671. DOI: 10.1038/s41569-018-0013-0. View

Wang X, Liu D, Zhang X, Yang L, Xia Z, Zhang Q . Exosomes from adipose-derived mesenchymal stem cells alleviate sepsis-induced lung injury in mice by inhibiting the secretion of IL-27 in macrophages. Cell Death Discov. 2022; 8(1):18. PMC: 8744023. DOI: 10.1038/s41420-021-00785-6. View

Willis G, Fernandez-Gonzalez A, Reis M, Yeung V, Liu X, Ericsson M . Mesenchymal stromal cell-derived small extracellular vesicles restore lung architecture and improve exercise capacity in a model of neonatal hyperoxia-induced lung injury. J Extracell Vesicles. 2020; 9(1):1790874. PMC: 7480622. DOI: 10.1080/20013078.2020.1790874. View

Zhou Y, Yamamoto Y, Xiao Z, Ochiya T . The Immunomodulatory Functions of Mesenchymal Stromal/Stem Cells Mediated via Paracrine Activity. J Clin Med. 2019; 8(7). PMC: 6678920. DOI: 10.3390/jcm8071025. View

Chen W, Huang Y, Han J, Yu L, Li Y, Lu Z . Immunomodulatory effects of mesenchymal stromal cells-derived exosome. Immunol Res. 2016; 64(4):831-40. DOI: 10.1007/s12026-016-8798-6. View

Liu J, Li C, Cao L, Zhang C, Zhang Z . Exosomal miR-132-3p from mesenchymal stem cells alleviated LPS-induced acute lung injury by repressing TRAF6. Autoimmunity. 2021; 54(8):493-503. DOI: 10.1080/08916934.2021.1966768. View

Sabapathy V, Kumar S . hiPSC-derived iMSCs: NextGen MSCs as an advanced therapeutically active cell resource for regenerative medicine. J Cell Mol Med. 2016; 20(8):1571-88. PMC: 4956943. DOI: 10.1111/jcmm.12839. View

Heo J, Choi Y, Kim H . Adipose-Derived Mesenchymal Stem Cells Promote M2 Macrophage Phenotype through Exosomes. Stem Cells Int. 2019; 2019:7921760. PMC: 6875419. DOI: 10.1155/2019/7921760. View

Winston T, Suddhapas K, Wang C, Ramos R, Soman P, Ma Z . Serum-Free Manufacturing of Mesenchymal Stem Cell Tissue Rings Using Human-Induced Pluripotent Stem Cells. Stem Cells Int. 2019; 2019:5654324. PMC: 6350554. DOI: 10.1155/2019/5654324. View

10.

Yin K, Wang S, Zhao R . Exosomes from mesenchymal stem/stromal cells: a new therapeutic paradigm. Biomark Res. 2019; 7:8. PMC: 6450000. DOI: 10.1186/s40364-019-0159-x. View

11.

Xu B, Chen S, Liu M, Gan C, Li J, Guo G . Stem cell derived exosomes-based therapy for acute lung injury and acute respiratory distress syndrome: A novel therapeutic strategy. Life Sci. 2020; 254:117766. DOI: 10.1016/j.lfs.2020.117766. View

12.

Zhang D, Lee H, Wang X, Rai A, Groot M, Jin Y . Exosome-Mediated Small RNA Delivery: A Novel Therapeutic Approach for Inflammatory Lung Responses. Mol Ther. 2018; 26(9):2119-2130. PMC: 6127502. DOI: 10.1016/j.ymthe.2018.06.007. View

13.

Lukomska B, Stanaszek L, Zuba-Surma E, Legosz P, Sarzynska S, Drela K . Challenges and Controversies in Human Mesenchymal Stem Cell Therapy. Stem Cells Int. 2019; 2019:9628536. PMC: 6481040. DOI: 10.1155/2019/9628536. View

14.

Liu C, Xiao K, Xie L . Advances in the use of exosomes for the treatment of ALI/ARDS. Front Immunol. 2022; 13:971189. PMC: 9396740. DOI: 10.3389/fimmu.2022.971189. View

15.

Ramos Y, Tertel T, Shaw G, Staubach S, Coutinho de Almeida R, Suchiman E . Characterizing the secretome of licensed hiPSC-derived MSCs. Stem Cell Res Ther. 2022; 13(1):434. PMC: 9438242. DOI: 10.1186/s13287-022-03117-2. View

16.

Cesetti T, Fila T, Obernier K, Bengtson C, Li Y, Mandl C . GABAA receptor signaling induces osmotic swelling and cell cycle activation of neonatal prominin+ precursors. Stem Cells. 2011; 29(2):307-19. DOI: 10.1002/stem.573. View

17.

Wei X, Yi X, Lv H, Sui X, Lu P, Li L . MicroRNA-377-3p released by mesenchymal stem cell exosomes ameliorates lipopolysaccharide-induced acute lung injury by targeting RPTOR to induce autophagy. Cell Death Dis. 2020; 11(8):657. PMC: 7438519. DOI: 10.1038/s41419-020-02857-4. View

18.

Jain R, DalNogare A . Pharmacological therapy for acute respiratory distress syndrome. Mayo Clin Proc. 2006; 81(2):205-12. DOI: 10.4065/81.2.205. View

19.

Wiklander O, Nordin J, OLoughlin A, Gustafsson Y, Corso G, Mager I . Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. J Extracell Vesicles. 2015; 4:26316. PMC: 4405624. DOI: 10.3402/jev.v4.26316. View

20.

Ti D, Hao H, Tong C, Liu J, Dong L, Zheng J . LPS-preconditioned mesenchymal stromal cells modify macrophage polarization for resolution of chronic inflammation via exosome-shuttled let-7b. J Transl Med. 2015; 13:308. PMC: 4575470. DOI: 10.1186/s12967-015-0642-6. View